Expansion Of HPV “High Risk” Type Group Entails “Tradeoff” – NEJM Article
This article was originally published in The Gray Sheet
Executive Summary
Five HPV DNA types previously classified as "low-risk" or "undetermined risk" should be added to the 13 types already linked to a "high" cervical cancer risk, according to a study by Nubia Munoz, MD, International Agency for Research on Cancer, Lyons, France, et al
You may also be interested in...
Digene DNA Pap Approval Anticipation Boosts Stock 45% In February
Investor expectations for imminent approval of Digene's HPV DNA Pap test as a primary screen for cervical cancer appeared to drive a 44.6% increase in the company's stock price to $16.59 in February
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.